Budget 2021: Rejigging Social Sector Spending Priorities in the Wake of COVID-19
Besides the health sector, which obviously needs to be strengthened, both NREGA and NRLM deserve an allocation boost.
A woman worker in the construction sector. Photo: Reuters/Adnan Abidi
Preparation for the presentation of Union Budget 2021-22 is underway.
Unlike in the past, it is expected that the priorities of this yearâs budget will be different. The pandemic-battered Indian economy is struggling to bring itself back on track due to its falling GDP growth rate, the rise in unemployment and the impact that COVID-19 has left on peopleâs health. While COVID-19, followed by the lockdown, has contracted Indiaâs GDP and revenue, demand for jobs, especially in the rural sector, and a shortage of health infrastructure need greater attention of the government.
Updated Jan 16, 2021 | 12:15 IST
The overall coronavirus tally in the country has reached 1,05,42,841, including 2,11,033 active cases. Representational Image.
New Delhi: India reported 15,158 new COVID-19 cases and 175 deaths in the last 24 hours, the Union Health Ministry said on Saturday.
The overall coronavirus tally in the country has reached 1,05,42,841, including 2,11,033 active cases.
With 16,977 discharges in the last 24 hours, the cumulative recoveries reached 1,01,79715. The death toll has gone up to 1,52,093.
With 67,711 active cases, Kerala is the worst affected state by Coronavirus in India currently, followed by Maharashtra, where there are 53,344 active COVID-19 cases.
According to the India Council of Medical Research (ICMR), a total of 18,57,65,491 samples were tested for COVID-19 till January 15, of which 8,03,090 samples were tested yesterday.
India COVID-19 update: 15,590 fresh cases; recovery rate reaches 96.53%
The number of people who have recuperated from the disease surged to 1,01,62,738 pushing the national COVID-19 recovery rate to 96.53 per cent
PTI | January 15, 2021 | Updated 11:36 IST
India COVID-19 news: There are 2,13,027 active cases of coronavirus infections in the country which comprises 2.02 per cent of the total caseload
India s COVID-19 caseload rose to 1,05,27,683 with 15,590 people testing positive for the infection in a day, while the recoveries have surged to 1,01,62,738, according to the Union health Ministry data updated on Friday.
The country s death toll increased to 1,51,918 with 191 daily new fatalities, the data updated at 8 am showed. The number of people who have recuperated from the disease surged to 1,01,62,738 pushing the national COVID-19 recovery rate to 96.53 per cent, while the COVID-19 case fatality rate stands at 1.44 per cent.
URL copied Image Source : PTI
India records 15,590 new COVID-19 cases, 191 deaths in a day; recovery rate rises to 96.53%
India s COVID-19 caseload rose to 1,05,27,683 with 15,590 people testing positive for the infection in a day, while the recoveries have surged to 1,01,62,738, according to the Union Health Ministry data updated on Friday.
The country s death toll increased to 1,51,918 with 191 daily new fatalities, the data updated at 8 am showed. The number of people who have recuperated from the disease surged to 1,01,62,738 pushing the national COVID-19 recovery rate to 96.53 per cent, while the COVID-19 case fatality rate stands at 1.44 per cent.
The COVID-19 active caseload remained below 3 lakh. There are 2,13,027 active cases of coronavirus infections in the country which comprises 2.02 per cent of the total caseload, the data stated. India s COVID-19 tally had crossed the 20-lakh mark on August 7, 30 lakh on August 23, 40 lakh on Sep
URL copied
File photo: Congress MP Manish Tewari speaks in the Lok Sabha. (Representational image)
At a time when vaccine distribution to states across India is in full swing ahead of the January 16 launch, the Congress party has raised questions on the safety, compatibility of India s homegrown Covid vaccine named COVAXIN, asking the government how it can be rolled out when it is yet to clear phase-3 trials. Congress MP Manish Tewari has upped the issue saying Indians are not guinea pigs (someone who is used for an experiment), raising doubts on Bharat Biotech s vaccine efficacy.
Congress has cautioned the government that since the Covaxin vaccine has not completed phase-3 trials, it should not be rolled out as Indians are not guinea pigs .